Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus entinostat in metastatic uveal melanoma
2016-002114-50Phase 2Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and entinostat in intraocular melanoma, sponsored by Sahlgrenska University Hospital. Primary endpoint: Objective response rate. Started Oct 2017; status: completed.
02
Drugs
pembrolizumabentinostat
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2016-002114-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002114-50.